AOD-9604: obesity evidence and cartilage research
AOD-9604 is a modified growth-hormone-derived peptide investigated in metabolic and cartilage research. Animal findings generated interest, but they do not establish human fat loss. FDA’s December 2024 assessment described a clinical obesity-development record that generally failed to show benefit over placebo.
Identity and formulation
AOD-9604 is not full-length growth hormone. The exact modified fragment should be specified rather than treating every HGH-fragment label as chemically equivalent.
Weight management and cartilage experiments address different indications and routes. A positive rabbit joint finding cannot rescue a failed human obesity endpoint.
What the studies show
The animal studies below are mechanistic and exploratory. The dated FDA assessment provides important context for the human development program, including a failed larger obesity study and limited publicly available detail. This is not evidence of proven spot reduction or a safe injectable weight-loss product.
| Study and design | Finding | What it does not establish |
|---|---|---|
| The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice.
Obese mice and beta-3-adrenoceptor knockout mice Reading scope: PubMed abstract and bibliographic record; not full-text review |
AOD9604 affected weight, body fat and lipid-metabolism measures in the experimental setting. | The study does not demonstrate human weight loss, and its receptor findings do not establish a simple direct beta-3 agonist mechanism. |
| Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model.
Collagenase-induced knee osteoarthritis model in 32 rabbits Reading scope: PubMed abstract and bibliographic record; not full-text review |
Cartilage-related scores and lameness measures differed among saline, hyaluronic acid, AOD9604 and combination groups. | These are induced-disease animal results. The combination group and single-agent groups must remain distinct. |
| Detection and in vitro metabolism of AOD9604.
Analytical identification and in vitro metabolism work Reading scope: PubMed abstract and bibliographic record; not full-text review |
The paper describes detection and characterization of the peptide and metabolites. | Detecting a substance is not evidence that it causes weight loss or repairs human cartilage. |
For the differences between a mechanism, a biomarker and a clinical outcome, see the evidence-reading guide.
How to interpret the findings
FDA’s December 2024 meeting transcript states that most identified studies failed to show a weight-reduction benefit versus placebo and that development for obesity was terminated after a failed study. That is a dated evidence assessment, not a statement about every current jurisdiction or formulation.
A result must be judged against its comparator. Within-group weight change, a mechanistic fat-oxidation signal and a between-group clinical weight-loss difference are not interchangeable.
Safety context
The material reviewed here does not justify calling every formulation free of growth-hormone-related effects or universally safe. A proposed separation of mechanisms requires evidence for the actual preparation and exposure.
Route matters. Data from an oral development program cannot automatically establish the safety of an injected catalog material.
Study exposure and units
Keep oral clinical development, systemic animal experiments and rabbit joint exposures separate. Their quantities and schedules do not form a common human protocol.
The study-exposure section should report route and species before any experimental amount. It should not convert a laboratory course into a personal cycle or local fat-loss instruction.
Match any reported amount or concentration to the exact material, route, population and duration in the original experiment. Read the guide to mass, volume and concentration for the meaning of common units. A calculation cannot establish an appropriate treatment or validate an untested formulation.
Product identity and report checks
Verify the exact modified sequence and chemical form, rather than relying only on HGH-fragment terminology.
A supplier report can help identify tested material; it cannot reverse the clinical obesity findings or establish equivalence to a trial preparation.
Keep the clinical evidence and the supplier evidence separate. Use the report-verification steps to check the issuer and the batch questions to connect a tested sample with the product offered. Compare prices using the delivered-cost method rather than an isolated discount or purity percentage.
Peptide Serum operates a store as well as this research library. The supplier directory contains imported seller information; a listing is not laboratory certification. Read how this library is prepared and evaluate the documentation for the exact lot offered. A seller rating does not establish clinical safety or effectiveness.
Common questions
Does AOD-9604 selectively remove fat near an application site?
The sources summarized here do not establish that claim in people. It should not be inferred from the fragment’s research rationale or from an unrelated local joint experiment.
Does the rabbit study prove cartilage regeneration in patients?
No. It reports a particular induced osteoarthritis model, with separate single-agent and combination groups. Human clinical outcomes require their own trials.
Sources
- The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. (PubMed abstract and bibliographic record; not full-text review)
- Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model. (PubMed abstract and bibliographic record; not full-text review)
- Detection and in vitro metabolism of AOD9604. (PubMed abstract and bibliographic record; not full-text review)
- FDA Pharmacy Compounding Advisory Committee transcript, December 4, 2024 (Official transcript text, relevant AOD-9604 efficacy section)